Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects who have advanced, recurrent or refractory FRa overexpressing tumors
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Elucida Oncology, Inc
Start Date
March 9, 2022
End Date
April 29, 2027
Administered By
Duke Cancer Institute
Awarded By
Elucida Oncology, Inc
Start Date
March 9, 2022
End Date
April 29, 2027